Stavens C S, McGovern B, Garan H, Ruskin J N
Am Heart J. 1985 Jul;110(1 Pt 1):24-9. doi: 10.1016/0002-8703(85)90509-5.
Propafenone is a new class Ic antiarrhythmic agent currently being investigated in the United States. It is generally well tolerated. We administered propafenone to 16 patients with ventricular tachycardia (VT) that had been refractory to conventional antiarrhythmic drug therapy. Three of these 16 patients developed electrically provoked incessant VT during treatment with propafenone without other evidence of toxicity. These arrhythmias subsided after lidocaine was administered. Propafenone therapy was discontinued in each case. Incessant VT did not develop in any of these patients in the absence of antiarrhythmic drugs or on antiarrhythmic drugs other than propafenone. Alternative effective treatment was identified for each patient. Although VT was initially provoked by pacing in each of these patients, these observations suggest that propafenone, like some other class Ic drugs, may favor the development of incessant VT in occasional patients. This appears most likely to occur in patients with ventricular dysfunction and prior sustained VT or ventricular fibrillation.
普罗帕酮是一种新型Ic类抗心律失常药物，目前正在美国进行研究。它通常耐受性良好。我们对16例对传统抗心律失常药物治疗无效的室性心动过速（VT）患者给予了普罗帕酮治疗。在这16例患者中，有3例在接受普罗帕酮治疗期间出现了电诱发的持续性室性心动过速，且无其他毒性证据。给予利多卡因后，这些心律失常消失。每种情况下均停用了普罗帕酮治疗。在没有抗心律失常药物或使用除普罗帕酮以外的其他抗心律失常药物时，这些患者中没有一例发生持续性室性心动过速。为每位患者确定了替代的有效治疗方法。尽管这些患者最初均通过起搏诱发室性心动过速，但这些观察结果表明，普罗帕酮与其他一些Ic类药物一样，可能会使少数患者发生持续性室性心动过速。这种情况最有可能发生在有心室功能障碍以及既往有持续性室性心动过速或心室颤动的患者中。
